Kazia Therapeutics Secures $40 Million in Oversubscribed Public Offering

The offering, priced at $15.50 per American Depositary Share, attracted participation from several institutional investors, including ADAR1 Capital Management, Columbia Threadneedle Investments, and Marshall Wace. The capital raised is earmarked primarily for advancing the development of paxalisib, the company’s lead drug candidate, which targets the PI3K/Akt/mTOR pathway in various cancer types, including triple-negative breast cancer and pMMR colorectal cancer.

The financing structure ties future funding to specific clinical performance. Investors received Series A and Series B warrants exercisable at premiums of 15% and 25%, respectively. These exercise prices are linked directly to upcoming data readouts for Stage IV triple-negative breast cancer, expected in late 2027, and HR+/HER2- breast cancer, anticipated in the first half of 2028. Leerink Partners and Guggenheim Securities served as joint bookrunning managers for the transaction.

Kazia management plans to discuss the impact of this financing and provide an update on its broader clinical strategy during a conference call scheduled for September 1, 2026. The company currently maintains a diverse portfolio that ranges from advanced clinical trials for paxalisib to preclinical programs focused on immunotherapy resistance, such as its PD-L1 protein degrader, NDL2.